Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Transurethral prostatectomy remains the mainstay of interventional treatment for men with significant symptoms or complications of bladder outflow obstruction. It is currently being challenged by new, less invasive modalities such as laser treatment, although randomized trials have not yet been sufficiently large to compare new technologies with conventional treatments satisfactorily. Transurethral prostatectomy carries risks of death of 0.2-0.5%, early return to theatre of 2%, sepsis of 8% and bleeding of 2-5%. These risks are increased in the elderly, those with retention, renal impairment and prostate cancer. The evidence is not compelling that transurethral prostatectomy carries significantly increased risks of late cardiovascular morbidity compared with age-matched controls.

Original publication




Journal article


Current Opinion in Urology

Publication Date





147 - 150